Haberler: Kovid-19

Kovid-19

İçinde

("Covid 19","Kovid 19","Koronavirüs","Korona virüs","Biontech","Sinovac","Delta ","Lambda ","Covid19","Kovid19","Covid-19","Kovid-19","Omicron ","Omikron ")

kelimelerinden biri ile,

(" aşı","vaccine","varyant","variant","pandemi","vaka "," dalga","pandemic","salgın")

kelimelerinden birinin aynı anda geçtiği haberler

Çarşamba, 18 Mayıs 2022, 12:05 ÖÖ	Haber Kaynağı: Çeşitli Haber Siteleri Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination - Five U.S. Mass Vaccination Sites, April 2021 Five mass vaccination sites reported 64 anxiety-related events, including 17 events of syncope (fainting) after receipt of Janssen COVID-19 vaccine. The reporting rates of syncope to VAERS after Janssen COVID-19 and influenza vaccines (2019-20) were 8.2 and 0.05 per 100,000 doses, respectively. https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=421542

Çarşamba, 18 Mayıs 2022, 12:05 ÖÖ	Haber Kaynağı: Çeşitli Haber Siteleri Linked Clusters of SARS-CoV-2 Variant B.1.351 - Maryland, January-February 2021 This report describes an investigation in Maryland of two linked clusters of COVID-19 cases identified as the B.1.351 variant. https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=421458

Çarşamba, 18 Mayıs 2022, 12:05 ÖÖ	Haber Kaynağı: Çeşitli Haber Siteleri Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years - United States, January-March 2021 In U.S. hospitals during January-March 2021, receipt of Pfizer-BioNTech or Moderna COVID-19 vaccines was 94% effective against COVID-19 hospitalization among fully vaccinated adults and 64% effective among partially vaccinated adults aged ≥65 years. https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=421438

Çarşamba, 18 Mayıs 2022, 12:05 ÖÖ	Haber Kaynağı: Çeşitli Haber Siteleri Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021 Nearly 8 million doses of the Janssen COVID-19 vaccine had been administered. Review of safety monitoring data found that 97% of reported reactions after vaccine receipt were nonserious, consistent with preauthorization clinical trials data. A total of 17 thrombotic events with thrombocytopenia were detected, including three non-CVST events. https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=421539

Çarşamba, 18 Mayıs 2022, 12:05 ÖÖ	Haber Kaynağı: Çeşitli Haber Siteleri Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021 The Advisory Committee on Immunization Practices concluded that the benefits of resuming Janssen COVID-19 vaccination among persons aged ≥18 years outweighed the risks and reaffirmed its interim recommendation under FDA's Emergency Use Authorization, which includes a new warning for rare clotting events among women aged 18-49 years. https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=421416

Çarşamba, 18 Mayıs 2022, 12:05 ÖÖ	Haber Kaynağı: Çeşitli Haber Siteleri COVID-19 Outbreak Associated with a SARS-CoV-2 R.1 Lineage Variant in a Skilled Nursing Facility After Vaccination Program - Kentucky, March 2021 In a COVID-19 outbreak at a Kentucky skilled nursing facility involving a newly introduced variant to the region, unvaccinated residents and health care personnel (HCP) had 3.0 and 4.1 times the risk of infection as did vaccinated residents and HCP. Vaccine was 86.5% protective against symptomatic illness among residents and 87.1% protective among HCP. https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=420773

Çarşamba, 18 Mayıs 2022, 12:05 ÖÖ	Haber Kaynağı: Çeşitli Haber Siteleri Postvaccination SARS-CoV-2 Infections Among Skilled Nursing Facility Residents and Staff Members - Chicago, Illinois, December 2020-March 2021 Twenty-two possible breakthrough SARS-CoV-2 infections occurred among fully vaccinated persons ≥14 days after their second dose of COVID-19 vaccine. Two thirds of persons were asymptomatic. A minority of persons with breakthrough infection experienced mild to moderate COVID-19-like symptoms; two COVID-19-related hospitalizations and one death occurred. No facility-associated secondary transmission was identified. https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=420772

Çarşamba, 18 Mayıs 2022, 12:05 ÖÖ	Haber Kaynağı: Çeşitli Haber Siteleri Trends in Racial and Ethnic Disparities in COVID-19 Hospitalizations, by Region - United States, March-December 2020 Within each U.S. Census region, the proportion of hospitalized patients with COVID-19 was highest for Hispanic or Latino patients. Racial and ethnic disparities were largest during May-July 2020 and became less pronounced as the pandemic spread throughout the country; however, disparities remained in December 2020 in all regions. https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=420182

Çarşamba, 18 Mayıs 2022, 12:05 ÖÖ	Haber Kaynağı: Çeşitli Haber Siteleri Notes from the Field: Update on Excess Deaths Associated with the COVID-19 Pandemic - United States, January 26, 2020-February 27, 2021 This report provides an update on excess deaths in the United States associated with the COVID-19 pandemic. https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=420529

Çarşamba, 18 Mayıs 2022, 12:05 ÖÖ	Haber Kaynağı: Çeşitli Haber Siteleri Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021 mRNA COVID-19 vaccine effectiveness against SARS-CoV-2 infection was 90% for full immunization (≥14 days after second dose) and 80% for partial immunization (≥14 days after first dose but before second dose) in real-world conditions. https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=419354